|Table of Contents|

Correlation of serum MTA1 concentration to clinical characteristics of nasopharyngeal carcinoma and its prognosis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 06
Page:
926-929
Research Field:
Publishing date:

Info

Title:
Correlation of serum MTA1 concentration to clinical characteristics of nasopharyngeal carcinoma and its prognosis
Author(s):
Tao Haoyun; Liao Kai; Yuan Taize
Department of Radiation Oncology,Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Guangdong Guangzhou 510095,China.
Keywords:
nasopharyngeal carcinoma; metastasis-associated protein 1; prognosis; metastases
PACS:
R739.6
DOI:
10.3969/j.issn.1672-4992.2020.06.012
Abstract:
Objective：To detect the level of MTA1 in the serum of patients with nasopharyngeal carcinoma and to explore its correlation with clinical characteristic and the prognosis.Methods:Pretreatment serum specimens and clinical data were collected from 96 patients who were newly diagnosed with non-metastatic NPC in our hospital from March 2011 to April 2015.The expression of serum MTA1 was detected by ELISA and classified into low or high-expression using a 50% cut-off level.The relationships of MTA1 with clinical characteristics and survival of patients were analyzed by univariate and multivariate analysis.Results:The median concentration of serum MTA1 in the whole group was 112 pg/ml（0~8 215 pg/ml).The median follow-up time was 47 months.23 patients developed distant metastasis.The level of MTA1 was related to distant metastasis（P=0.031),but there was no relation between MTA1 and gender,age,T,N stage and clinical stage.Univariate survival analysis showed that the 4-year DMFS in MTA1 high-expression group was 73.2%,which was significantly lower than that in MTA1 low-expression group 86.7%（P=0.039).The 4-year PFS in MTA1 high-expression group and MTA1 low-expression group tended to be significant difference（70.8% vs 87.3%,P=0.054).Although the 4-year OS in MTA1 high-expression group was poor than that in MTA1 low-expression group,there was no significance（82.1% vs 86.9%,P=0.091).Furthermore,multivariate analysis revealed that pretreatment serum MTA1 expression was not an independent prognostic factor for DMFS,PFS and OS of NPC patients（P=0.106,P=0.126,P=0.349).Conclusion:The high expression of pretreatment serum MTA1 is related with DMFS of NPC patients.

References:

[1] Lee Anne WM,Tung Stewart Y,Ng Waitong,et al.A multicenter,phase 3,randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma:10-year outcomes for efficacy and toxicity［J］.Cancer,2017,123(21):4147-4157.
[2] Wu MY,He XY,Hu CS.Tumor regression and patterns of distant metastasis of T1-T2 nasopharyngeal carcinoma with intensity-modulated radiotherapy ［J］.PLoS One,2016,11(4):e0154501.
[3] Kaur E,Gupta S,Sudeep D,et al.Clinical implications of MTA proteins in human cancer［J］.Cancer and Metastasis Reviews,2014,33(4):1017-1024.
[4] Ma K,Fan Y,Dong D,et al.MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer ［J］.Oncotarget,2017,8(24):38825-38840.
[5] Lee MH,Koh D,Na H,et al.MTA1 is a novel regulator of autophagy that induces tamoxifen resistance in breast cancer cells ［J］.Autophagy,2018,14(5):812-824.
[6] Honjoh H,Toh Y,Sohda M,et al.Clinical significance and phenotype of MTA1 expression in esophageal squamous cell carcinoma ［J］.Anticancer Res,2017,37(8):4147-4155.
[7] Deng YF,Zhou DN,Ye CS,et al.Aberrant expression levels of MTA1 and RECK in nasopharyngeal carcinoma:Association with metastasis,recurrence,and prognosis ［J］.Ann Otol Rhinol Laryngol,2012,121(7):457-465.
[8] Yuan TZ,Zhang HH,Liu BQ,et al.Expression of MTA1 in nasopharyngeal carcinoma and its correlation with prognosis ［J］.Medical Oncology,2014,31(12):330.
[9] Rao Y,Wang H,Fan L,et al.Silencing MTA1 by RNAi reverses adhesion,migration and invasiveness of cervical cancer cells（SiHa) via altered expression of p53,and E-cadherin/β-catenin complex ［J］.Journal of Huazhong University of Science and Technology(Medical Sciences),2011,31(1):1-9.
[10] Kumar A,Dhar S,Campanelli G,et al.MTA1 drives malignant progression and bone metastasis in prostate cancer ［J］.Molecular Oncology,2018,12(9):1596-1607.
[11] Pakala SB.MTA1 promotes STAT3 transcription and pulmonary metastasis in breast cancer ［J］.Cancer Research,2013,73(12):3761-3770.
[12] Nagaraj SR,Rayala SK,Wang RA,et al.Crosstalk between VEGF and MTA1 signaling pathways contribute to aggressiveness of breast carcinoma ［J］.Molecular Carcinogenesis,2015,54(5):333-350.
[13] Lu B,Lian R,Wu Z,et al.MTA1 promotes viability and motility in nasopharyngeal carcinoma by modulating IQGAP1 expression ［J］.Journal of Cellular Biochemistry,2018,119(5):3864-3872.
[14] Xu CH,Hua F,Chen TH,et al.MTA1 promotes metastasis of MPM via suppression of E-cadherin ［J］.Journal of Experimental & Clinical Cancer Research,2015(34):151.

Memo

Memo:
广州市卫生局资助项目（编号：20161A011087）
Last Update: 2020-01-21